Nesfatin-1 levels in patients with slow coronary flow

10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Background: Nesfatin-1 is a novel anorectic neuropeptide with potent metabolic regulatory effects. Aim: We aimed to evaluate the relationship between nesfatin-1 levels and slow coronary flow (SCF). Methods: A total of 60 consecutive patients with SCF and 60 consecutive patients with normal coronary flow (NCF) were enrolled into the study. Nesfatin-1 level was measured from blood serum samples using enzyme-linked immunosorbent assay test. Results: Serum nesfatin-1 levels were significantly lower in the SCF group compared to the NCF group (p < 0.001). Low levels of nesfatin-1 were found to be significantly and independently associated with the SCF (odds ratio 0.982, 95% confidence interval 0.969-0.995, p = 0.005). Conclusions: The results of this study showed that serum nesfatin-1 level was lower in the SCF group than in the NCF group. Nesfatin-1 could play a role in the pathogenesis of SCF phenomenon with mechanisms such as inflammation and endothelial dysfunction. Further studies are needed to determine the relation between SCF and nesfatin-1.

Cite

CITATION STYLE

APA

Kuyumcu, M. S., Kuyumcu, A., Yayla, Ç., Özbay, M. B., Alagöz, M., Ünal, S., … Samur, G. (2018). Nesfatin-1 levels in patients with slow coronary flow. Kardiologia Polska, 76(2), 401–405. https://doi.org/10.5603/KP.a2017.0210

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free